Skip to content
← Full study record

NCT02953340 · MORE INFO

Limitations, agreements, and source contact

SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide · Source last updated 2022-03-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
pi Sponsor Employee
false
restrictive Agreement
true
point Of Contact
email
shanta.chawla@sppirx.com
organization
Spectrum Pharmaceuticals Inc. Research and Development Office 157 Technology Drive Irvine, CA 92618
phone
(949) 788-6700
title
Shanta Chawla
Complete source fields
certain Agreement
pi Sponsor Employee
false
restrictive Agreement
true
point Of Contact
email
shanta.chawla@sppirx.com
organization
Spectrum Pharmaceuticals Inc. Research and Development Office 157 Technology Drive Irvine, CA 92618
phone
(949) 788-6700
title
Shanta Chawla

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice